That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19.

Matthew R DavisErin K McCrearyJason M Pogue

Published in: Infectious diseases and therapy (2020)

Remdesivir is a nucleoside antiviral recently studied in several randomized trials for treatment of COVID-19. The available observational and prospective data are conflicting, requiring clinicians to critically evaluate and reconcile results to determine patient populations that may optimally benefit from remdesivir therapy, especially while drug supply is scarce. In this review, we analyze pertinent clinical remdesivir data for patients with COVID-19 from January 1, 2020, through May 31, 2020.

Keyphrases

coronavirus disease
sars cov
electronic health record
big data
case report
emergency department
data analysis
cross sectional
artificial intelligence
bone marrow
deep learning
cell therapy